Allan Coukell

@coukell

In the stew of health policy, drugs, devices, food, FDA, epidemiology, pharmacy. Also bicycles. I direct health programs at Pew, but tweets are my own.

Washington, DC
pewtrusts.org/en/topics/heal…
2013年10月加入
77 個相片或影片 圖片與影片

推文

你已封鎖 @coukell

你確定要查看這些推文嗎？查看推文並不會將 @coukell 解除封鎖

  1. 5月14日

    There are real issues with pharma marketing, but it seems wrong to imply there is some marketing v R&D tradeoff. Presumably, every $ on marketing increases revenue by more than was spent, thus increasing the *potential* R&D spend.

    On average, pharmaceutical industry is spending $1 out of every $5 of revenue on research and development. What's the right amount? How much is spent on marketing? via
    2 則轉推 1 個喜歡
    還原
  2. 已轉推
    5月13日

    a growing industry of unregulated stem cell clinics. What could possibly go wrong?

    3 則轉推 2 個喜歡
    還原
  3. 已轉推
    5月13日

    As the Opioid Crisis Peaks, Meth and Cocaine Deaths Explode via

    3 則轉推 3 個喜歡
    還原
  4. 5月13日

    . has contributed more than 10,000 additional data points to ’s open-access antibiotic research platform.

    6 則轉推 11 個喜歡
    還原
  5. 已轉推
    5月9日

    The entire DC council has supported some new action to advance vision zero in the wake of recent traffic fatalities. Hey , next week would be a great time to announce that you’re going to let build the 6th/9th st bike lanes you’ve been blocking for 4 years!

    3 replies 8 則轉推 37 個喜歡
    顯示此對話串
    顯示此對話串
    還原
  6. 5月7日

    Where are the state consumer protection folks in all this?

    3/ - A mother donates her birth tissue for free. - A manufacturer makes a vial of product for <$50 - The maker sells it to a distributor or direct to a clinic for ~$1k. - A clinic charges $5k-$10k per treatment. Patients pay out of pocket.
    顯示此對話串
    2 則轉推 7 個喜歡
    還原
  7. 已轉推
    5月7日

    Notable that the long history of legislation establishing increased security over U.S. drug supply, including PDMA and DQSA, the closed supply chain, and the modern pedigree; were all passed in part or large measure as a result of counterfeit drug problems originating in Florida.

    3 replies 15 則轉推 34 個喜歡
    顯示此對話串
    顯示此對話串
    還原
  8. 已轉推
    5月7日

    1 則轉推 4 個喜歡
    顯示此對話串
    顯示此對話串
    還原
  9. 5月2日

    Jeff Shuren: one barrier to development of antimicrobial diagnostics is they are LDTs and payers won’t cover. Hopefully, Congress will move forward with LDT reform.

    回覆給 @Frank_S_David
    Maker of a qualifying abx gets a TEV they sell to the highest bidder who then uses it to get added exclusivity on some other drug, extending its time on market without generic competition. So sale price of TEV has to be exceeded by increased revenue (ie taxpayer costs)
    1 則轉推 1 個喜歡
    還原
  10. 5月2日

    Also, the downside of a transferable exclusivity voucher is that it sticks taxpayers with higher costs for non-antibiotic drugs, with only a portion of that spend accruing to the antibiotic developer.

    Antibiotics “market failures” — smart thinking from in this piece by . My addl 2c — w/ any new incentives, also need plan for cost/benefit analysis, along lines suggested by ; see
    1 replies 2 則轉推 2 個喜歡
    還原
  11. 5月2日

    Article omits fact that antibiotics already get 10 yrs exclusivity under GAIN, not 5. Additional measures are needed, but focus now is on reimbursement reform and market entry rewards.

    Antibiotics “market failures” — smart thinking from in this piece by . My addl 2c — w/ any new incentives, also need plan for cost/benefit analysis, along lines suggested by ; see
    2 則轉推 1 個喜歡
    還原
  12. 5月1日

    My friend, you are missed at Pew, but we are delighted that you have landed well. has picked up one of the smartest people around on drug spending policy.

    After a hiatus, I'm back to health policy Twitter. More importantly, I have a new role at the Policy Center. Very excited!
    3 個喜歡
    還原
  13. 已轉推
    4月30日

    For years, the focus on medical errors has been on medications. Now more attention on medical devices. UDI key to understanding not only when things go wrong but also which products work best on which patients.

    1 replies 17 則轉推 21 個喜歡
    還原
  14. 已轉推
    4月29日

    The House draft FY20 Labor-HHS appropriations bill is out (h/t )! 2 aspects show it’s the same story, different (fiscal) year. 1-House approps proposes ONC budget @ $60M, rejecting White House bid to slash funds 2-ban on $ for a unique patient ID persists

    1 replies 5 則轉推 5 個喜歡
    還原
  15. 已轉推
    4月29日

    Between 1999 and 2015, overdose deaths increased 325 percent in rural counties. fact sheet addresses the challenges and opportunities found in rural communities for improving access to high-quality care.

    5 則轉推 5 個喜歡
    還原
  16. 已轉推
    4月27日

    A Workable Alternative To Nursing Homes In Vermont — Adult Family Care

    3 則轉推 1 個喜歡
    還原
  17. 已轉推
    4月26日

    ⁦⁩ urges people get . An important public health message.

    2 replies 3 則轉推 3 個喜歡
    還原
  18. 4月26日

    Expanding the breadth of patients included in ’s measures of prescribing would create a fuller picture of antibiotic use for common respiratory conditions.

    2 則轉推 1 個喜歡
    還原
  19. 4月24日

    A bunch of "health care professionals" selling products that kill hundreds of thousands of Americans each year.

    If Walgreens really wants to make an impact on tobacco use among teens, they should stop selling tobacco products. At the very least, they should stop selling kid-friendly e-cigarette flavors.
    2 則轉推 1 個喜歡
    還原
  20. 4月24日

    Electronic health records have improved many aspects of health care, but they can also contribute to safety risks and risk serious treatment errors. investigates 12 cases involving children.

    4 則轉推 13 個喜歡
    還原

@coukell 尚未發表任何推文。

看來要一段時間讀取資料。

Twitter 可能已超出負載，或發生暫時性的小問題。請再試一次，或造訪 Twitter 狀態以取得更多資訊。

    你也可能也會喜歡

    ·